This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results
The median cost was £724.72 (IQR 676.74 to 773.85 ) with ablation and £230.24 (IQR 123.20 to 259.91) with sclerotherapy (p<0.0005).
The above-knee great saphenous vein occlusion rate (without co-existing reflux), at three months, was not significantly different between the groups (74% for ablation and 69% for sclerotherapy; p=0.596). The median AVVQ score, at three months was 5.8 (IQR 2.5 to 12.2) for ablation and 12.4 (IQR six to 21.9) for sclerotherapy (p=0.062). The VCSS was one (IQR zero to three) for ablation and two (IQR one to four) for sclerotherapy (p=0.817). The venous filling index was 1.5mL per second (IQR 1.1 to 2.4) for ablation and 1.9mL per second (IQR 1.3 to 2.7) for sclerotherapy (p=0.791).
The median pain score in the seven days following treatment was 33 out of 100 (IQR 18 to 54) with ablation and 14 out of 100 (IQR six to 34) with sclerotherapy (p=0.005).
